SECOND TEAM
Julie Hudson & team UBS
Newcomer Julie Hudson — who, according to one supporter, “has a broad and deep experience of the equity markets, both in terms of sectors and geographies” — guides the previously unranked UBS trio to second place. In November the analysts teamed up with Gbola Amusa, the firm’s head of European pharmaceuticals research, to publish a report recommending GlaxoSmithKline, at 1,223p, making the case that the Brentford, England–based pharmaceuticals manufacturer has a history of distributing drugs free of charge in emerging markets where there are unmet medical needs — and that the company is well positioned to expand its operations within those markets, which represent a key growth opportunity over the long term. By the end of the year, the stock had risen to 1,240p.